SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH M impact

Viridian Therapeutics Reports Third-Quarter 2026 Results

Viridian reported $24.7 million in Lumvoa net product revenue, with more than 100 patients on therapy.

VRDN
SquawkNews Desk 2 updates Updated Nov 04, 2026, 12:32 PM UTC

Story updates

12:28:34 PM UTC
SquawkNews
Viridian posts first Lumvoa revenue but net loss widens Overview U.S. biotech firm reported first ne
12:32:51 PM UTC
SquawkNews
*-- Earnings Flash (VRDN) Viridian Therapeutics, Inc. Reports Q3 Revenue $25.8M

Related stories

Neuronetics Q3 Revenue Reaches $41.962 Million Neuronetics reported Q3 revenue of USD 41.962 million, versus the IBES estimate of USD 40.4 million. M impact | EQUITY | Nov 04, 2026, 12:51 PM UTC Neuronetics Reports Third-Quarter Loss per Share M impact | EQUITY | Nov 04, 2026, 12:50 PM UTC Neuronetics Reports Lower Q3 2026 Net Loss and Higher Revenue M impact | EQUITY | Nov 04, 2026, 12:50 PM UTC Neuronetics Reports Third-Quarter Revenue of $42M M impact | EQUITY | Nov 04, 2026, 12:50 PM UTC Datadog Reports Higher Third-Quarter Profit and Revenue Datadog reported quarterly profit of $118.3 million, or 32 cents a share, with revenue also higher. The report attributes growth to continued platform adoption and increased custom M impact | EQUITY | Nov 04, 2026, 12:50 PM UTC Neuronetics Reports Third-Quarter 2026 Results Neuronetics reported third-quarter 2026 financial and operating results. M impact | EQUITY | Nov 04, 2026, 12:50 PM UTC